Profile data is unavailable for this security.
About the company
Frontier Biotechnologies Inc is a China-based company principally engaged in the research and development, production, and sales of drugs. The Company's products mainly include long-acting anti-human immunodeficiency virus (HIV) drugs, small nucleic acid drugs, and high-end generics. The long-acting anti-HIV drugs mainly include Aikoning. The small nucleic acid drugs mainly include FB7011, FB7013, and FB7014 and others. The high-end generics mainly include FB4001 and FB3002 and others. The Company's drugs are mainly used for the treatment of acquired immune deficiency syndrome (AIDS), abnormal blood lipids, and osteoporosis.
- Revenue in CNY (TTM)141.20m
- Net income in CNY-167.73m
- Incorporated2013
- Employees302.00
- LocationFrontier Biotechnologies IncHi-Tech Park, Jiangning DistrictNANJING 211199ChinaCHN
- Phone+86 2 569648375
- Fax+86 2 569748373
- Websitehttps://www.frontierbiotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jiangsu Aidea Pharmaceutical Group Co Ld | 671.33m | -87.10m | 7.08bn | 704.00 | -- | 7.24 | -- | 10.54 | -0.207 | -0.207 | 1.60 | 2.32 | 0.3558 | 1.01 | 4.33 | 953,592.70 | -3.23 | -4.33 | -5.23 | -5.36 | 63.08 | 40.16 | -9.09 | -20.35 | 1.03 | -2.12 | 0.3093 | -- | 1.57 | 3.89 | -85.63 | -- | 5.88 | -- |
| Lushang Freda Pharmaceutical Co Ltd | 3.78bn | 214.11m | 7.34bn | 3.63k | 34.19 | 1.75 | -- | 1.94 | 0.2112 | 0.2112 | 3.72 | 4.12 | 0.633 | 3.37 | 7.63 | 1,040,448.00 | 4.45 | 0.7994 | 6.29 | 5.29 | 51.41 | 23.96 | 7.02 | 3.71 | 3.96 | -- | 0.0393 | 43.21 | -13.02 | -17.29 | -19.73 | -6.70 | 21.16 | 0.00 |
| Heilongjiang ZBD Pharmaceutical Co Ltd | 1.60bn | -332.62m | 7.36bn | 2.35k | -- | 1.01 | -- | 4.61 | -0.3545 | -0.3545 | 1.70 | 7.75 | 0.1303 | 0.6358 | 0.4977 | 679,399.90 | -2.74 | 3.29 | -3.80 | 4.46 | 44.16 | 37.24 | -21.03 | 10.59 | 1.33 | -1.45 | 0.3114 | 24.43 | -13.90 | -3.87 | -7.30 | 1.41 | 1.13 | -7.12 |
| Frontier Biotechnologies Inc | 141.20m | -167.73m | 7.38bn | 302.00 | -- | 7.52 | -- | 52.26 | -0.4478 | -0.4478 | 0.377 | 2.62 | 0.0775 | 1.78 | 2.74 | 467,559.50 | -9.21 | -12.65 | -12.08 | -14.50 | 32.51 | 18.59 | -118.79 | -333.96 | 2.58 | -- | 0.3472 | -- | 13.32 | 44.07 | 38.78 | -- | -35.01 | -- |
| Wuhan Keqian Biology Co Ltd | 1.01bn | 459.54m | 7.61bn | 924.00 | 16.66 | 1.82 | -- | 7.50 | 0.9796 | 0.9796 | 2.16 | 8.95 | 0.2209 | 2.86 | 3.23 | 1,097,706.00 | 9.97 | 11.71 | 11.17 | 13.56 | 65.26 | 73.57 | 45.16 | 44.51 | 5.02 | -- | 0.0017 | 32.23 | -11.48 | 13.17 | -3.43 | 9.52 | -4.93 | -- |
| Cisen Pharmaceutical Co Ltd | 3.56bn | 492.80m | 7.65bn | 3.30k | 15.58 | 1.24 | -- | 2.15 | 1.08 | 1.08 | 7.84 | 13.59 | 0.472 | 2.10 | 5.34 | 1,079,074.00 | 6.58 | 6.51 | 8.12 | 8.07 | 53.70 | 55.92 | 13.94 | 10.84 | 3.48 | -- | 0.0069 | 37.16 | -10.77 | -0.6464 | -2.38 | -0.2215 | -0.3051 | 10.42 |
| Zhejiang Ausun Pharmaceutical Co Ltd | 751.12m | 184.84m | 7.81bn | 1.22k | 41.98 | 3.33 | -- | 10.40 | 0.2241 | 0.2241 | 0.8963 | 2.83 | 0.2472 | 0.9248 | 3.00 | 616,180.10 | 6.08 | 8.91 | 7.77 | 12.10 | 51.51 | 53.44 | 24.61 | 27.68 | 2.17 | -- | 0.1383 | 27.35 | -2.63 | 20.90 | -18.55 | 29.68 | 17.53 | 43.79 |
Data as of Mar 03 2026. Currency figures normalised to Frontier Biotechnologies Inc's reporting currency: Chinese Yuan Renminbi CNY
3.30%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 3.34m | 1.62% |
| Hui'an Fund Management Co. Ltd.as of 30 Jun 2025 | 2.24m | 1.09% |
| Guotai Asset Management Co., Ltd.as of 30 Jun 2025 | 375.90k | 0.18% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 264.13k | 0.13% |
| Shanghai Guotai Junan Securities Assets Management Co., Ltd.as of 30 Jun 2025 | 133.38k | 0.07% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 117.20k | 0.06% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 108.23k | 0.05% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 82.11k | 0.04% |
| BOSC Asset Management Co. Ltd.as of 30 Jun 2025 | 68.50k | 0.03% |
| CCB Principal Asset Management Co., Ltd.as of 30 Jun 2025 | 67.89k | 0.03% |
More ▼
Data from 30 Jun 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
